We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy

By LabMedica International staff writers
Posted on 04 Aug 2016
In type 1 diabetic patients who have progressed to the final stages of nephropathy, kidney failure eventually develops in 50% of individuals within 10 years after the onset of overt nephropathy and in greater than 75% by the 20-year mark.

Nephropathy is diagnosed through the detection of increased urinary albumin excretion, but a growing body of evidence suggests that the risk for developing diabetic nephropathy starts when urinary albumin excretion levels are still within the normal range. More...
If the onset of nephropathy could be detected before urinary albumin rises, patients could potentially be placed on treatment to prevent its development.

A team of scientists at the Aghia Sophia Children’s Hospital (Athens, Greece) has determined that two proteins, growth differentiation factor-15 (GDF-15) and chitinase-3-like protein 1 (YKL-40), could be used to detect diabetic nephropathy early. The team tested 56 type 1 diabetes patients mean age 13.1 ± 3.2 years and 49 healthy controls ages 12.8 ± 6.6 years, for GDF-15 and YKL-40 which were performed by means of immunoenzymatic and immunonephelometric techniques at time of enrollment in the study and after 12 to15 months. Also at these two time points, they evaluated subjects’ kidney function by measuring cystatin C to determine estimated glomerular filtration rate (eGFR) and measuring neutrophil gelatinase associated lipocalin (NGAL).

The teams found that after 12 to 15 months, GDF-15 levels in diabetes patients were significantly higher at 366.7 pg/mL than in healthy controls at 278.6 pg/mL. Initially, no significant difference in YKL-40 measurements was observed between diabetes patients and controls at time of enrollment, but over the course of the study, mean YKL-40 levels in diabetes patients proceeded to increase from 17.4 ng/mL to 20.5 ng/mL. GDF-15 levels also correlated negatively with eGFR values, while YKL-40 levels correlated positively with NGAL and GDF-15, indicating that rises in both proteins reflect a decline in kidney function.

Ioannis Papassotiriou, PhD, the team leader, said, “This is the first study to demonstrate a predictive role for serum GDF-15 and YKL-40 as early markers of diabetic nephropathy in children and adolescents with type 1 diabetes before severe overt nephropathy occurs. Defining new predictors as supplementary tests to urinary albumin excretion for the early diagnosis of diabetic nephropathy could accelerate effective management and treatment approaches needed to minimize the rates of severe renal morbidity and mortality in young patients with type 1 diabetes.”

Related Links:
Aghia Sophia Children’s Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.